GLP‑1 Receptor Agonists in Non‑Diabetic Chronic Kidney Disease: A Systematic Review
DOI:
https://doi.org/10.71749/pkj.120Keywords:
Glucagon‑Like Peptide‑1 Receptor Agonists/therapeutic use, Kidney Failure, Chronic/drug therapy, Renal Insufficiency, Chronic/drug therapyAbstract
Introduction: Glucagon- like peptide- 1 receptor agonists have demonstrated cardiovascular and kidney benefits in type 2 diabetes, but their role in non- diabetic chronic kidney disease remains uncertain.
Methodology: A systematic review following PRISMA 2020 guidelines was conducted, in which MEDLINE (PubMed), Cochrane Library, TRIP and NICE databases were used. Search strategies combined MeSH terms and free- text strategies. Eligible studies included randomized controlled trials, observational studies, systematic reviews, meta- analyses and clinical practice guidelines published in English, Portuguese or Spanish. A thorough examination of reference lists was conducted to identify additional studies. Evidence was graded using the Strength of Recommendation Taxonomy.
Results: The final synthesis included two placebo-controlled randomized trials. In the SELECT trial, non- diabetic adults with overweight or obesity and established cardiovascular disease who received semaglutide 2.4mg2.4mg once weekly showed a slower decline in estimated glomerular filtration rate and approximately 22%22% fewer composite kidney events compared with placebo, with a greater benefit in those with baseline estimated glomerular filtration rate below 60mL/60mL/ min/1.73m2min/1.73m2 . In the SMART trial, adults with non- diabetic chronic kidney disease and overweight or obesity experienced a 52%52% reduction in albuminuria at 24 weeks with semaglutide, while measured and estimated glomerular filtration rate remained stable.
Conclusion: These findings suggest potential benefits of glucagon-like peptide- 1 receptor agonists on albuminuria and kidney function trajectories independent of diabetes, but effects on long- term kidney outcomes remain unknown. Use in this population should be individualized and further studies are required to validate this use.
Downloads
References
GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:2461-82. doi:10.1016/S0140-6736(25)01853-7
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. doi:10.1056/NEJMoa1603827
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44. doi:10.1056/NEJMoa1607141
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131-38. doi:10.1016/S0140-6736(19)31150-X
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-21. doi:10.1056/NEJMoa2403347
Muskiet MHA, Tonneijck L, Smits MM, an Baar MJ, Kramer MH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13:605-28. doi:10.1038/nrneph.2017.123
Chen JY, Hsu TW, Liu JH, Pan HC, Lai CF, Yang SY, et al. Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis. 2025;85:555-69. doi:10.1053/j.ajkd.2024.11.013
Mendonça L, Moura H, Chaves PC, Neves JS, Ferreira JP. The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials. Clin J Am Soc Nephrol. 2024;20:159-68. doi:10.2215/CJN.0000000584
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-S314. doi:10.1016/j.kint.2023.10.018
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:71. doi:10.1136/bmj.n71
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17:59-67. doi:10.3122/jabfm.17.1.59
Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30:2058-66. doi:10.1038/s41591-024-03015-5
Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31:278-85. doi:10.1038/s41591-024-03327-6
Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15-28. doi:10.1016/S2213-8587(24)00271-7
Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025;31:544-51. doi:10.1038/s41591-024-03374-2
Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA, et al. Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85:1721-35. doi:10.1016/j.jacc.2025.03.009
Wu R, Xing B, Zhou Z, Yu L, Wang H. Effect of semaglutide on arrhythmia, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Eur J Med Res. 2025;30:835. doi:10.1186/s40001-025-03124-y
Skibicka A, Malgorzewicz S. Visceral obesity and metabolic dysfunction in IgA nephropathy: nutritional and metabolic perspectives on disease progression. Nutrients. 2025;17:3307. doi:10.3390/nu17203307
Bjornstad P, Cherney D, Lawson J, Møntegaard C, Pruijm M, Tuttle K, et al. Remodel: a mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2022;37:i290-i291. doi:10.1093/ndt/gfac070.013
Heerspink HIL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128-39. doi:10.1016/S2213-8587(18)30314-0
ClinicalTrials.gov. Efficacy and Safety of a GLP-1 Receptor Agonist in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Identifier: NCT06582875. [accessed Oct 2025] Available at: https://clinicaltrials.gov/study/NCT06582875
ClinicalTrials.gov. A Study of Tirzepatide on Renal Oxygenation and Cardio-Renal Outcomes in Patients with Overweight or Obesity and Chronic Kidney Disease. Identifier: NCT04777409. [accessed Oct 2025] Available at: https://clinicaltrials.gov/study/NCT05536804
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Isabel Ralha de Abreu, Mariana R. Marques
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
